Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Gemcitabine + JNJ-87801493 + JNJ-95566692 + Oxaliplatin + Rituximab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Gemcitabine Gemzar Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 Chemotherapy - Antimetabolite 14 Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).
JNJ-87801493 JNJ 87801493|JNJ87801493 CD20 Antibody 29 CD28 Antibody 14 JNJ-87801493 is a bispecific antibody targeting CD20 on B-cells and CD28 on T-cells, which potentially enhances T-cell activation and inhibits tumor growth (Blood (2024) 144 (Supplement 1): 1408).
JNJ-95566692 JNJ95566692|JNJ 95566692 CD20 Antibody 29 CD3 Antibody 128 Limited information is currently available on JNJ-95566692, a putative trispecific antibody targeting CD79b, MS4A1 (CD20), and CD3 (Feb 2026).
Oxaliplatin Eloxatin Diaminocyclohexane Oxalatoplatinum Chemotherapy - Platinum 7 Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).
Rituximab Rituxan IDEC-C2B8|MabThera CD20 Antibody 29 Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT07308132 Phase I Cyclophosphamide + Doxorubicin + JNJ-95566692 + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + JNJ-87801493 + JNJ-95566692 + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + JNJ-95566692 + Prednisone + Rituximab + Vincristine Sulfate JNJ-87801493 + JNJ-95566692 + Lenalidomide JNJ-95566692 + Lenalidomide Gemcitabine + JNJ-87801493 + JNJ-95566692 + Oxaliplatin + Rituximab Gemcitabine + JNJ-95566692 + Oxaliplatin + Rituximab JNJ-87801493 + JNJ-95566692 + Loncastuximab tesirine-lpyl JNJ-95566692 + Loncastuximab tesirine-lpyl JNJ-87801493 JNJ-87801493 + JNJ-95566692 JNJ-95566692 Cyclophosphamide + Doxorubicin + JNJ-87801493 + JNJ-95566692 + Polatuzumab vedotin-piiq + Prednisone + Rituximab A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies Recruiting TUR | FRA | ESP | BEL | AUS 0


Additional content available in Icon for CKB-BoostCKB BOOST